SCHEMBL3883300

SCHEMBL3883300

CN(C)CCCOc1cccc(NC(=O)C(=O)c2c(-c3ccccc3)cc3ccccn23)c1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.59
SMN1; SMN2 Q16637 5/20 0.59
MAPT P10636 5/20 0.59
LMNA P02545 4/20 0.59
HTT P42858 3/20 0.53
THRB P10828 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.51
FAAH O00519 1/20 0.45
KDM4E B2RXH2 4/20 0.44
KDM1A O60341 1/20 0.43
MAOB P27338 1/20 0.43
KMT2A Q03164 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
CACNA1B Q00975 2/20 0.40
KDR P35968 1/20 0.40
ESR1 P03372 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1646696 0.95 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL3883500 0.88 SMN1; SMN2 (0.57) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1646578 0.85 MAPT (0.60) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1644516 0.84 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1644775 0.83 MAPT (0.61) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1647753 0.82 MAPT (0.59) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1645406 0.81 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1644750 0.79 L3MBTL1 (0.69) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1647401 0.79 MAPT (0.66) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL1645339 0.78 THRB (0.61) ALDH1A1SMN1; SMN2MAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 ALDH1A1 510/4885SMN1; SMN2 3501/4885MAPT 2792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.